tbuckley/cabot-search huggingface dataset:
MPTH-27. ACTIVITY REPORT OF A REGIONAL MOLECULAR DIAGNOSTIC NETWORK FOR CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN JAPAN
Authors: Kanji Mori, Tomoko Shofuda, Yoshiko Okita, Hideyuki Arita, Manabu Kinoshita, Yuzo Terakawa, Naohiro Tsuyuguchi, Yusuke Tomogane, Junya Fukai, Kenichi Ishibashi, Namiko Nishida, Takuya Taki, Masahiro Nonaka, Shuichi Izumoto, Shusuke Moriuchi, Yoshikazu Nakajima, Nagoya Hashimoto, Yoshinori Kodama, Yonehiro Kanemura
Journal: Neuro-Oncology (2016)

According to the progress of rapid and large-scale genetic analysis and therapeutic strategies based on big data about intractable diseases, biobank has been more valuable. Although results obtained from molecular analysis have to be immediately used clinically, treatments based on such informations are performed almost only in research institutes in our country. Since 2007, we have built a network system for CNS tumor banking and genetic analysis beyond hospital categories in Kansai area. In this meeting, we will present recent progresses and problems, and discuss future directions of our system. We compared number of participating institutes, collaboration works, collected and analyzed samples during 2015 and before 2014. Then we discussed on our capacity of analysis and storage to meet quality standards for further researches. At present, a total of twenty-four institutes and hospitals are participating in this network. We have collected 477samples at the end of 2014, and newly stored 247 samples during 2015. 303 cases of them are certificated as newly diagnosed tumors. All specimens were analyzed and reported regarding methylation status of MGMT promoter, mutations of IDH1/2, TP53, and TERT promoter. We also tested deletion of 1p/19q for oligodendrogliomas, and BRAF V600 mutation and fusion genes for pilocytic astrocytoma. These data were reported as our own two researches in scientific meetings, and over 150 cases were registered to two other multi-center studies. Tumor samples and clinical data have been accumulating and analyzing with minimal issue. Now this network has became one of the valuable research network systems for CNS tumors in Japan. But to collect and handle more minute clinical information from many cases are upcoming important problem. In the near future, we have to establish a sustainable system and to satisfy international standards of CNS tumor biobank.
Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Authors: M.E. Gutierrez, G. Giaccone, S.V. Liu, A. Rajan, U. Guha, T.R. Halfdanarson, K.K. Curtis, P.L. Kunz, N. Gabrail, J.M. Hinson, E.O. Orlemans
Journal: Annals of Oncology (2016)
CNS tumours The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas
Authors: M.W. Kieran, E. Bouffet, U. Tabori, A. Broniscer, K. Cohen, J. Hansford, B. Geoerger, P. Hingorani, I. Dunkel, M. Russo, L. Tseng, Q. Liu, N. Nebot, J. Whitlock, D. Hargrave
Journal: Annals of Oncology (2016)
EPID-18. DEMOGRAPHICAL PRESENTATION AND SURVIVAL OUTCOME OF ASTROCYTOMA IN CENTRAL TEXAS
Authors: Damir Nizamutdinov, Jad Dandashi, Eileen Stock, Samantha Dayawansa, Jun Zhang, Ekokobe Fonkem, Erxi Wu, Jason Huang
Journal: Neuro-Oncology (2016)

To explore the distribution and epidemiology of astrocytomas within a Central Texas patient population in order to elucidate any possible differences in epidemiologic and prognostic factors based on age, primary tumor location, gender, and ethnicity. Eight hundred forty five clinical cases of astrocytoma were obtained from the tumor registry of the Scott and White Integrated Healthcare System from 1976 to 2013. We investigated the effects of gender, race, tumor grade, surgical method, recurrence, radiation therapy, chemotherapy, and mortality of patients. Prevalence data echoes that of the national epidemiology in that among our sample, White individuals had the highest prevalence (n=666, 78.8%), followed by Hispanic (n=94, 11.1%), and Black individuals (n=78, 9.2%). White patients had higher rates of parietal lobe (6.6% vs. 0.6%, p<0.01), brain overlapping (6.8% vs. 0.0%, p<0.01), and brainstem (5.9% vs. 1.7%, p=0.02) tumors. Black patients had higher rates of tumors located in brain, not otherwise specified (NOS) (35.9% vs. 15.7%, p<0.01), and cerebellum (33.3% vs. 5.6%, p<0.01). Hispanic patients had higher rates of tumor located in the temporal lobe (31.9% vs. 22.8%, p<0.05) and brain NOS (28.7% vs. 16.1%, p<0.01). Hispanic patients had largest proportion of deceased (72.3% vs. 38.0%, p<0.01) when compared to the remainder of the sample, followed by White individuals (39.6% vs 49.7%, p=0.02), and Black individuals (21.8% vs. 43.8%, p<0.01). Discrepancies in mortality rates amongst various racial groups may due to a number of factors. Primary tumor site and histology seem to indeed play a role in mortality and may present various factors including genetic predisposition, environmental and occupational exposure and inequity in access to healthcare.
APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)
Authors: A. Necchi, L. Mariani, A. Anichini, P. Giannatempo, D. Raggi, E. Togliardi, G. Calareso, N. Di Genova, F. Crippa, R. Salvioni
Journal: Annals of Oncology (2016)
TMOD-36. GENE EXPRESSION ANALYSIS OF SHORT AND LONG SURVIVAL GROUPS OF GLIOBLASTOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS
Authors: David Cherba, Laila Poisson, Mary Winn, Hoon Kim, Roel G.W. Verhaak, Tom Mikkelsen, Ana C. deCarvalho
Journal: Neuro-Oncology (2016)

Few molecular markers predictive of glioblastoma patient prognosis are MGMT promoter methylation, IDH1/2 mutation and G-CIMP status. Gene expression, on the other hand, has been less robust in predicting survival, in part due to the influence and variability of the hosts. Here we present analysis of gene expression patterns in relation to glioblastoma tumor aggressivity in uniform murine hosts, using glioblastoma patient-derived xenograft (PDX) models. Neurosphere cultures established from IDH1/2 wildtype glioblastomas were implanted orthotopically in cohorts of 10 to 15 nude mice, for development of PDX. Mice were monitored and sacrificed when symptomatic. Five PDX lines, presenting median survival of 29 to 59 days were classified as short (S) survivors, and 5 lines with median survival between 111 and 134 days as long (L) survivors. Mean patient age at diagnosis was 56 years and 55 years for the L and S PDX groups, respectively. Total RNA was extracted from PDX terminal tumors (3 biological replicates) and sequenced using Illumina HiSeq 2000 in a paired-end read format. RNA sequencing BAM files were generated and gene expression was measured as RPKM. Mouse reads were filtered out using Xenome. Differential gene expression analysis between tumors in S and L survival groups was conducted using the lmFit and eBayes, and genes were ranked by Benjamini-Hochberg adjusted P-values, set to adj.p<0.05, resulting in 1663 genes upregulated and 1539 genes downregulated in the S group. Median overall survival for untreated PDX did not correlate to overall patient survival, given the demographic and clinical covariates such as age, extent of resection and treatment modalities. Genes significantly associated with cell cycle, DNA-damage response, neoplasmas, genomic instability and epigenetic regulation were upregulated, while neural development genes were downregulated in the S group. The comparative analysis of PDX panels has the potential to elucidate tumor intrinsic molecular correlates of agressivity.
Patient-reported toxicity after colorectal cancer (CRC) treatment.
Authors: C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, G. A. Di Lullo, J. M. Metz
Journal: Journal of Clinical Oncology (2011)

484 Background: Colorectal cancer patients may be at risk for myriad late effects after multimodality therapy, the impact of which may difficult to evaluate using conventional methods. This Internet-based study evaluates patient perceptions of toxicity after treatment for CRC. Methods: Patient-reported data was gathered via a convenience sample frame from CRC survivors voluntarily utilizing a publically available, free, Internet-based tool for creation of survivorship care plans. Available at www.livestrongcareplan.com and through the OncoLink website, the tool allows survivors to enter data regarding diagnosis, demographics, and treatments, and provides customized guidelines for future care. During use of the tool, CRC survivors are queried regarding late effects associated with specific treatments, and asked to answer “yes,” “no,” or “I don't know.” They are also asked to score GI toxicity using WHO criteria. All data have been maintained with IRB approval. Results: 148 CRC survivors answered queries regarding late effects; 64% were female and 82% Caucasian. Median diagnosis age was 50 (24-76) and median current age 54 (24-77). Most reported having had multimodality therapy - 97% surgery, 89% chemotherapy, and 37% radiation. When queried regarding GI toxicity, 51% reported chronic changes in bowel patterns, 34% chronic diarrhea, 12% bowel obstruction, 18% hernia development, 8% radiation colitis, and 2% fistula formation. Of 18 survivors who graded GI toxicity, 27% reported 4-6 stools per day, and 22% &gt; 6 stools per day or incontinence. When queried regarding sexual function, 31% of men reported worse erectile function than pre-treatment, and 39% of women reported sexual changes such as vaginal dryness. Perceived cognitive decline since diagnosis of cancer was reported by 57%. Conclusions: Survivors using this tool anonymously and voluntarily report significant GI toxicity after cancer treatment. Approximately 1/3 of male and female survivors report impact on sexual function, and more than 50% report perceived cognitive decline. This tool offers a unique way for survivors to report their experiences; the data reported here may be of significant impact in future study of quality of life, as well as patient counseling and survivor care. No significant financial relationships to disclose.
EPID-09. INCIDENCE OF GLIOMA IN A MIXED URBAN-RURAL COMMUNITY OF NORTH AMERICA: A POPULATION-BASED STUDY
Authors: Conor Ryan, Harsheen Kaur
Journal: Neuro-Oncology (2016)

Limited information is known about incidence trends of glioma and its characteristics in well-defined populations, especially in a mixed urban-rural setting of North America. We assessed glioma incidence and characterized it in the Olmsted County, Minnesota, population. This population-based study utilized the Mayo Clinic Tumor Registry and the Rochester Epidemiology Project (NIH-funded medical record linkage system for Olmsted County residents). We assessed incidence of pathologically confirmed glioma between January 1, 1995, and December 31, 2014. Age- and gender- adjusted incidence rates per 100,000 person-years were calculated using the 2010 US white population. We compared incidence trends of glioma during our study period with Olmsted County data from 1950-1990. World Health Organization grading was used. We identified 135 incident glioma cases (93% white) with 20 pediatric cases (< 20 years at diagnosis) (50% female) and 115 adult cases (≥20 years at diagnosis) (44% female). The overall incidence rate (all ages) during our study period, 5.5, was the same as that in 1950-1990, 5.5. Adult males, 7.87, had a higher rate than females, 5.23. Incidence of pediatric (age <20) glioma was 2.5 (95% CI: 1.4–3.6) and 1.5 for Grade I astrocytoma (60% of pediatric cases). Adult glioma was 6.5 (95% CI: 5.3–7.7) overall and 4.3 for glioblastoma. Incidence rates increased from 2.11 for age 20-29 years to 11.51 for age 60+ years, most noticeably increasing after age 50. Glioblastoma became the predominant tumor type after age 40 (77%), while occurring in only 12% of adults <40 years. Majority (68%) of tumors in ages 20-39 were grade II/III. Given its methodology, this study likely offers the most reliable data for (1) assessing incidence of glioma by grade, and (2) trending glioma incidence, which appears stable to studies from this population dating back to 1950.
Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.
Authors: Caroline Alvares, Samar Kulkarni, Pawel Kaczmarek, Radovan Saso, Helena Woods, Joy Brennan, Clive Horton, Jennifer Treleaven, Mark Ethell, Claire Dearden, Gareth Morgan, Michael Potter
Journal: Blood (2006)
Cancer risks and mutation spectrum of mismatch repair genes in African American families with Lynch syndrome.
Authors: Sonia Kupfer, Rodrigo Santa Cruz Guindalini, Cassandra Gulden, Chinedu I Ukaegbu, Erika Koeppe, Peggy Conrad, Heather Hampel, Elena Martinez Stoffel, Sapna Syngal, Olufunmilayo I. Olopade
Journal: Journal of Clinical Oncology (2013)

1530 Background: Although African Americans (AA) have the highest colorectal cancer (CRC) incidence and mortality of all populations in the United States, no studies have determined cancer risk and mismatch repair (MMR) genes mutation spectrum in LS patients of AA ancestry and the contribution of this syndrome to cancer disparities. Thus, the aims of this study are: (1) to describe LS cancers in AAs; (2) to investigate the mismatch repair (MMR) gene mutation spectrum in AA families with LS; (3) to determine how Amsterdam II criteria, revised Bethesda guideline, and PREMM(1,2,6) model perform for predicting MMR gene mutations in this population. Methods: Pedigrees of AA families with deleterious mutation or suspected deleterious mutation in MMR genes from five US referral centers were analyzed for personal and familial clinical cancer histories. Results: Twenty-four AA families were identified, of which 22 had deleterious mutations (15 MLH1, 4 MSH2, 2 MSH6, 1 PMS2) and 2 had suspected deleterious mutations (1 MLH1, 1 MSH2). Three recurrent mutation were found in MLH1(677G&gt;A, IVS1-2A&gt;G, IVS4-1G&gt;A), accounting for 25% of all mutations. Of 24 probands, 58% were female and 96% had personal history of cancer. The median age at first primary tumor was 42yrs (range 28-57) and 50% developed more than 1 primary tumor. The majority of probands (79%) had CRC (median age of onset – 42yrs [range 31-61]), of which 26% had at least 2 CRC primaries. Endometrial cancer developed in 50% of the women (median age of onset – 51yrs [range 32-57]). Amsterdam II and Bethesda criteria were met in 63% and 88% of the individuals, respectively. Median score by PREMM(1,2,6) model was 54% (range 12.9-99.8). Conclusions: To our knowledge, this is the largest series of AA families with LS reported to date. Earlier age of onset for CRC at 42yrs (previously reported ~45 yrs) is suggested. The majority of mutations were found in MLH1 (67%), including three recurrent mutations. A 10% cutoff for PREMM(1,2,6) predictive model identified all mutation carriers. Larger studies are warranted to confirm the differences observed in age of CRC onset in this population.
Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in advanced leiomyosarcoma and angiosarcoma
Authors: B. Vincenzi, S. Stacchiotti, P. Collini, F. Pantano, C. Rabitti, G. Perrone, M. Iuliani, A. Baldi, G. Badalamenti, R. Sanfilippo, D. Santini, A. Onetti Muda, A. Gronchi, P. Casali, A.P. Dei Tos, G. Tonini
Journal: Annals of Oncology (2016)
Early Development of Immunity to CMV Following Hematopoietic-Stem Cell Transplantation Is Associated with Graft-Versus Leukaemia Effect
Authors: Valérie Guérin-El Khourouj, Raphaël Porcher, Sandrine Leveille, Jérôme Le Goff, Béatrice Pédron, Andre Baruchel, Jean-Hugues Dalle, Ghislaine Sterkers
Journal: Blood (2012)
Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)
Authors: R.D.M. Linck, P.F. Asprino, F.P. Freitas, F.C. Koyama, P.A.F. Galante, R. Riechelmann, L.F.L. Reis, F.P. Costa, P.M. Hoff, A.A. Camargo, J. Sabbaga
Journal: Annals of Oncology (2016)
Risk for Endemic Burkitt Lymphoma Is Elevated in Children Who Are Resistant to Blood-Stage Plasmodium Falciparum Malaria Infection: Preliminary Results from the Emblem Study
Authors: Samuel Kirimunda, Tobias Kinyera, Martin Ogwang, Steven J Reynolds, Moses Joloba, Ruth M Pfeiffer, James J. Goedert, Kishor Bhatia, Sam M Mbulaiteye
Journal: Blood (2014)
Palliative treatment the malignant trachea-bronchial stenosis.
Authors: Renjie Yang
Journal: Journal of Clinical Oncology (2014)

70 Background: To evaluate the safety and usefulness of interventional procedure and stent placement in palliative care the patients with malignant trachea-bronchial stricture. Methods: All 52 lung cancer patient, male 38, female 14, age from 27~82 years old. On pathological type: squamous cell carcinoma 31, small cell carcinoma 11, adenocarcinoma 8 and cystadenocarcinoma 2 cases respectively. Clinical symptoms consist of severe dyspnea, choke and fever. For the interventional materials are guide wire, single curved catheter, coaxial delivery set and expandable metallic stent (Gianturco Z stent, wallstent and home-made NiTi alloy stent). Results: Totally 62 stents were planted in 52 cases, successful rate was 100%. The symptoms of dyspnea immediately relieved after stent placement. The slight stimulate cough usually recovered within 1 week. Following the stenting 17 patients accepted radiation, 21 patients got systematic chemotherapy; and 3 cases done pulmonary lesions cryoablation. Stent inside stent was done in 7 cases because tumor ingrowth. The immediate imaging showed the stricture segment of trachea lumen was dilated in varied degree. The implanted stents were dilated perfectly within one week and there was no stent migration on follow up. Conclusions: The trachea-bronchial stenosis caused by lung cancer can be palliative managed by stent implantation. It’s a good method to improve patient’s quality of life and benefit for the patient continue therapeutics.
Risk Factors for Central Venous Line-Related Deep Vein Thrombosis and Occlusions in the Israeli Pediatric Oncology Registry.
Authors: Shoshana Revel-Vilk, Joanne Yacobovich, Hannah Tamary, Gal Goldstein, Isaac Yaniv, Amos Toren, Polina Stephanski, Michael Weintraub, Gili Kenet
Journal: Blood (2008)
Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies
Authors: Farhad Khimani, Daniel K. Jeong, Taiga Nishihori, Ernesto Ayala, Joseph A Pidala, Frederick L. Locke, Gage Kenneth, Julio C. Chavez, Claudio Anasetti, Mohamed A. Kharfan-Dabaja
Journal: Blood (2015)
HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma
Authors: X. Chen, L. Gao, E.M. Sturgis, Z. Liang, Y. Zhu, X. Xia, X. Zhu, X. Chen, G. Li, Z. Gao
Journal: Annals of Oncology (2017)

Molecular evidence suggests that human papillomavirus (HPV) has a role in the etiology of oropharyngeal squamous cell carcinoma. However, the role of HPV in laryngeal squamous cell carcinoma (LSCC) is unclear.We conducted a case-control study using tumor tissue specimens from 300 LSCC patients and vocal cord polyp specimens from 300 cancer-free controls. HPV genotype, HPV16 viral load and viral integration status, and p16 expression were determined.The prevalence of HPV (all types) was higher in cases than controls [21 (7.0%) versus 10 (3.3%), adjusted odds ratio (aOR) 2.37, 95% CI 1.08-5.21]. The prevalence of HPV16 was higher in cases than controls [20 (6.7%) versus 8 (2.7%), aOR 2.84, 95% CI 1.21-6.68]. The risk of LSCC associated with HPV16 DNA positivity was even higher in patients aged 55 years or younger (aOR 3.52, 95% CI 1.07-11.54), males (aOR 4.74, 95% CI 1.33-16.90), never-smokers (aOR 5.57, 95% CI 1.41-22.10), and never-drinkers (aOR 3.72, 95% CI 1.09-12.72). HPV DNA was partly or fully integrated in all 20 HPV16-positive cases but was episomal in all 8 HPV16-positive controls; however, the HPV16-positive cases and controls had similar viral loads (P = 0.28). P16 immunostaining was positive in 31 of the 300 cases (10.3%) and negative in all 300 controls.These results suggest that prior infection with HPV16 may play a role in the etiology of some LSCC. This larger case-control study will offer for the first time the possibility to address in depth the understanding of a tissue-specific role of HPV in laryngeal carcinogenesis. Further studies with larger samples are needed to confirm these findings.
Medical oncologists' attitudes towards vaccination in oncology practice
Authors: A. Alkan, E. Karcı, A. Yaşar, G. Tuncay, M. Ürün, E.B. Köksoy, Y. Ürün, F. Çay Şenler, G. Utkan, A. Demirkazık, H. Akbulut
Journal: Annals of Oncology (2016)
A Murine Marrow-Derived Multipotent Stem Cell Line Could Reconstitute Hematopoiesis after Transplantation into Lethallly Irradiated Syngeneic Mice.
Authors: Huiying Qiu, Hong Zhou, Rong Xia, Shenglan Gong, Lei Gao, Xiaoxia Hu, Jianmin Wang
Journal: Blood (2005)
Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)
Authors: Sarah Waheed, Bijay Nair, Yazan Alsayed, Monica Grazziutti, Elias J. Anaissie, Frits van Rhee, Nathan Petty, Doug Steward, Jackie Szymonifka, Antje Hoering, John Crowley, Bart Barlogie
Journal: Blood (2010)
Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.
Authors: Apostolia-Maria Tsimberidou, Susan O’Brien, Issa Khouri, Francis J. Giles, Hagop M. Kantarjian, Sijin Wen, Susan C. Smith, Susan Lerner, Emil J. Freireich, Michael J. Keating
Journal: Blood (2005)
Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
Authors: M. Puzzoni, G. Pusole, R. Mascia, L. Demurtas, A. Dessì, A. Cubeddu, E. Lai, S. Tolu, P. Ziranu, L. Orgiano, V. Pusceddu, G. Astara, C. Madeddu, E. Massa, L. Casula, G. Palmieri, M. Scartozzi
Journal: Annals of Oncology (2016)
Efficient and Rapid In Vitro Generation of Multi-Virus-Specific CD4+ and CD8+ T Cells for Adoptive Immunotherapy.
Authors: Anne Richter, Anna Foerster, Verena Lasmanowicz, Olaf Brauns, Sven Kramer, Petra Jekow, Wolfgang Rönspeck, Mario Assenmacher, Juergen Schmitz
Journal: Blood (2010)
Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation
Authors: Takahiko Nakane, Mika Nakamae, Hideo Koh, Mitsutaka Nishimoto, Yoshiki Hayashi, Asao Hirose, Yasuhiro Nakashima, Masayuki Hino, Hirohisa Nakamae
Journal: Blood (2015)
Assessment of the Effect of Nilotinib (Tasigna) Maintenance Therapy After Allogeneic Stem Cell Transplantation in Patients with Advanced CML and Ph+ ALL On Immune Reconstitution and Lymphocyte Function
Authors: Nira Varda-Bloom, Raz Somech, Yulia Volchek, Jacqueline Davidson, Atar Lev, Ronit Yerushalmi, Avichai Shimoni, Arnon Nagler
Journal: Blood (2012)
CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US
Authors: Kamal Chamoun, Hagop M. Kantarjian, Mary Beth Rios, Rita Assi, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D DiNardo, Tapan M. Kadia, Naveen Pemmaraju, Elias J. Jabbour, Jorge E. Cortes
Journal: Blood (2016)
Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496
Authors: Ranjana Advani, Fangxin Hong, Richard I Fisher, Nancy L. Bartlett, Sue Robinson, Randy D. Gascoyne, Henry Wagner, Patrick J Stiff, Bruce D. Cheson, Douglas A. Stewart, Leo I Gordon, Brad Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph Tuscano, Richard Hoppe, Sandra J. Horning
Journal: Blood (2010)